SLC5A2 and hydrops fetalis: Current HF guidelines recommend (1) renin angiotensin aldosterone system (RAAS) inhibitors (angiotensin-converting enzyme inhibitors (ACEIs) angiotensin II receptor blockers (ARBs) in cases of ACEI intolerance, or the angiotensin receptor neprilysin inhibitor (ARNI); (2) beta-blockers (BB); (3) mineralocorticoid receptor antagonists (MRA); and (4) sodium glucose cotransporter-2 (SGLT2) inhibitors (regardless of the presence or absence of diabetes) for all symptomatic HFrEF patients [3,4].